Joe Mitchell: The One Big Beautiful Bill Undercut The Medicare Program’s Ability To Negotiate Drug Prices, An Estimated $8.8 Billion Benefit For Pharmaceutical Companies At The Expense Of Seniors
The Congressional Budget Office Estimated The One Big Beautiful Bill’s Delay And Exemption Of Certain Pharmaceutical Drugs From The Medicare Drug Price Negotiation Program Would Cost $8.8 Billion Over 10 Years. “You have asked the Congressional Budget Office to provide a revised estimate of the budgetary effects of section 71203 of the 2025 reconciliation act. That section delays or exempts certain drugs from selection for the Medicare Drug Price Negotiation Program, which directed the Department of Health and Human Services to negotiate with pharmaceutical manufacturers for the prices that Medicare will pay for certain drugs covered under Part B and Part D of the program. CBO’s July 2025 estimate did not include the effects of the policy on price negotiation for several orphan drugs, including Darzalex (daratumumab) Keytruda (pembrolizumab), and Opdivo (nivolumab). […] After accounting for the effect of the policy on those additional drugs, CBO now estimates the cost of section 71203 at $8.8 billion for the 2025–2034 period, $3.9 billion more than the original estimate.” [Congressional Budget Office, Revised Estimate of Changes Under the 2025 Reconciliation Act for Exemptions From Medicare Price Negotiations for Orphan Drugs, 10/20/25]
- Congressional Budget Office: The Medicare Drug Price Negotiation Program “Directed The Department Of Health And Human Services To Negotiate With Pharmaceutical Manufacturers For The Prices That Medicare Will Pay For Certain Drugs.” “You have asked the Congressional Budget Office to provide a revised estimate of the budgetary effects of section 71203 of the 2025 reconciliation act. That section delays or exempts certain drugs from selection for the Medicare Drug Price Negotiation Program, which directed the Department of Health and Human Services to negotiate with pharmaceutical manufacturers for the prices that Medicare will pay for certain drugs covered under Part B and Part D of the program.” [Congressional Budget Office, Revised Estimate of Changes Under the 2025 Reconciliation Act for Exemptions From Medicare Price Negotiations for Orphan Drugs, 10/20/25]
Office Of Congressman Frank Pallone Jr: “A New Report From The Congressional Budget Office Found A Provision Hidden Away In Trump’s Signature Bill Will Give An Enormous $8.8 Billion Sweetheart Deal To Big Pharma Companies At The Expense Of Seniors.” “The details of Trump’s so-called ‘Big Beautiful Bill’ keep getting uglier. A new report from the Congressional Budget Office found a provision hidden away in Trump’s signature bill will give an enormous $8.8 billion sweetheart deal to Big Pharma companies at the expense of seniors. While Republicans were drafting the largest health care cut in history, they quietly tucked in language to weaken Medicare’s ability to negotiate lower drug prices for seniors. This is a trojan horse policy that will undermine efforts to lower prescription drug prices for years to come. According to CBO, the provision will give a windfall to pharmaceutical companies by preventing Medicare from negotiating prices for certain drugs, including cancer treatments like Keytruda, Opdivo, and Darzalex that seniors rely on.” [Office Of Congressman Frank Pallone Jr, Press Release, 10/20/25]